A potential way for overcoming immunotherapy resistance in patients with mucosal melanomas

The development of the anti-cancer immunotherapy drugs called immune checkpoint inhibitors has improved treatment for many cancer patients, but patients with mucosal melanomas -; melanomas that occur not on the skin but in the mucous membranes in the head, neck, eyes, respiratory tract, and genitourinary region -; are particularly resistant to immune checkpoint inhibitors for reasons researchers don't fully understand.

Related Keywords

Colorado ,United States ,Martin Mccarter ,Richard Tobin ,Theresa Medina ,Emily Henderson ,Cu Center ,University Of Colorado Cu Cancer Center ,University Of Colorado School Medicine ,Cu Cancer Center ,National Comprehensive Cancer Network ,Cancer Center ,Young Investigator Award ,Colorado School ,Kasey Couts ,Cancer ,Ancer Immunotherapy ,Fell ,Clinical Trial ,Drugs ,Efficacy ,Frequency ,Immunity ,Immunotherapy ,Melanoma ,Neck ,Research ,Espiratory ,Skin ,Humor ,